AUTHOR: R. Scott Hoffman, MD
The term conjunctivitis refers to an inflammation of the conjunctiva resulting from a variety of causes, including allergies and bacterial, viral, and chlamydial infections.
Pseudomembranous conjunctivitis
|
Occurs at any age. Most cases in adults are due to viral infection. Children are more prone to develop bacterial conjunctivitis than viral forms. Table E1 summarizes manifestations of acute conjunctivitis in children
TABLE E1 Manifestations of Acute Conjunctivitis in Children
FEATURE | CLINICAL CHARACTERISTICS | |
---|---|---|
BACTERIAL | VIRAL | |
Common pathogens | Haemophilus influenzae (usually nontypable) | Adenoviruses types 8, 19 |
Streptococcus pneumoniae | Enteroviruses | |
Moraxella catarrhalis | Herpes simplex virus | |
Incubation | 24-72 h | 1-14 days |
SYMPTOMS | ||
Photophobia | Mild | Moderate to severe |
Blurred vision | Common with discharge | If keratitis is present |
Foreign body sensation | Unusual | Yes |
SIGNS | ||
Discharge | Purulent discharge | Mucoid/serous discharge |
Palpebral reaction | Papillary response | Follicular response |
Preauricular lymph node | Unusual for acute (<10%) | More common (20%) |
Chemosis | Moderate | Mild |
Hemorrhagic conjunctivae | Occasionally with pneumococcus or Haemophilus sp. | Frequent with enteroviruses |
Treatment (topical) | Polymyxin B-trimethoprim orsulfacetamide 5% or erythromycin or moxifloxacin or gatifloxacin | Adenovirus: Self-limited Herpes simplex virus: Trifluridine 1% solution or ganciclovir 0.15% gel or acyclovir; ophthalmologic consultation |
End of contagious period | 24 h after start of effective treatment | 7 days after onset of symptoms |
From Marcdante KJ et al: Nelson essentials of pediatrics, ed 9, Philadelphia 2023, Elsevier.
Figure E2 Bacterial conjunctivitis.
Purulent discharge and conjunctiva hyperemia suggest bacterial conjunctivitis. Viral conjunctivitis produces watery discharge, foreign body sensation, preauricular lymphadenopathy, and conjunctival follicles seen on slit lamp examination.
Reproduced with permission from the American Academy of Ophthalmology. From Goldman L, Schafer AI: Goldmans Cecil medicine, ed 24, Philadelphia, 2012, Saunders.
Figure E3 Conjunctivitis: Papillary versus follicular.
The erythema of conjunctivitis (shaded dark gray) is most intense on the inside surface of the eyelids (tarsal conjunctiva) and peripherally on the globe (near the fornices), whereas the erythema is less intense centrally near the limbus. In more severe conjunctivitis, the entire conjunctival surface (both tarsal and bulbar) is red. This pattern of erythema contrasts with iritis, which causes more intense erythema centrally around the limbus, a finding called circumlimbal flush or ciliary flush. In patients with conjunctivitis, the clinician should inspect the everted upper or lower lids, noting whether the inner membrane has its normal smooth surface or instead has small, uneven projections, which are characterized as either papillae or follicles. In this example, the clinician has used his thumb to gently evert the lower lid for inspection. Papillae (left bottom) are contiguous red vascular bumps; the center of each papilla contains a blood vessel. They are red on the surface and pale at the base. Papillae are often so tiny that the conjunctiva acquires a velvety appearance, and only magnification reveals their true nature. Other times, papillae may become large and produce a cobblestone appearance. Follicles (right bottom) are discrete 1- to 2-mm-diameter white bumps consisting of aggregates of lymphoid tissue; the center of each is avascular. They are pale on the surface and red at the base.
From McGee S: Evidence-based physical diagnosis, ed 4, Philadelphia, 2018, Elsevier.
TABLE E2 Allergic Diseases of the Eye
Disease | Clinical Parameters | Signs and Symptoms | Differential Diagnosis |
---|---|---|---|
Seasonal allergic conjunctivitis (SAC) | Occurs in sensitized individuals Both females and males affected Bilateral involvement Seasonal allergens Self-limiting | Ocular itching Tearing (watery discharge) Chemosis, redness Often associated with rhinitis Not sight-threatening | Infective conjunctivitis Preservative toxicity (any eye drop with preservative) Medicamentosa Dry eye Perennial allergic conjunctivitis Vernal keratoconjunctivitis (VKC) Atopic keratoconjunctivitis (AKC) |
Perennial allergic conjunctivitis (PAC) | Occurs in sensitized individuals Both females and males affected Bilateral involvement Year-round allergens Self-limiting | Ocular itching Tearing (watery discharge) Chemosis, redness Often associated with rhinitis Not sight-threatening | Infective conjunctivitis Preservative toxicity Dry eyeSAC/AKC/VKC |
Atopic keratoconjunctivitis (AKC) | Occurs in sensitized individuals Peak incidence: 20-50 yr of age Both females and males affected Bilateral involvement Seasonal or perennial allergens Atopic dermatitis Chronic symptoms | Severe ocular itching Red, flaking periocular skin Mucoid discharge, photophobia Corneal erosions Scarring of conjunctiva Cataract (anterior subcapsular) Sight-threatening | Contact dermatitis Infective conjunctivitis Blepharitis PemphigoidVKC/SAC/PAC/GPC |
Vernal keratoconjunctivitis (VKC) | Occurs in some sensitized individuals Peak incidence: 3-20 yr of age Males predominate (in 3:1 ratio) Bilateral involvement Warm, dry climate Seasonal/perennial allergens Chronic symptoms | Severe ocular itching Severe photophobia Thick, ropy discharge Cobblestone papillae Corneal ulceration and scarring Sight-threatening | Infective conjunctivitis BlepharitisAKC/SAC/PAC/GPC |
Giant papillary conjunctivitis (GPC) | Sensitization not necessary Both females and males affected Bilateral involvement Prosthetic and contact lens exposure Occurs anytime Chronic symptoms Nonseasonal occurrence | Mild ocular itching Mild mucoid discharge Giant papillae Contact lens intolerance Foreign body sensation Protein buildup on contact lens Not sight-threatening | Infective conjunctivitis Preservative toxicitySAC/PAC/AKC/VKC |
From Adkinson NF et al: Middletons allergy principles and practice, ed 8, Philadelphia, 2014, Saunders.
TABLE E3 Histopathologic and Laboratory Manifestations of Allergic Ocular Disease
Disease | Histopathologic Features | Laboratory Manifestations |
---|---|---|
Seasonal/perennial allergic conjunctivitis | Mast cell/eosinophil infiltration in conjunctival epithelium and substantia propria Mast cell activation Upregulation of ICAM-1 on epithelial cells | Increased in tears: Specific IgE antibody Histamine Tryptase TNF-α |
Atopic keratoconjunctivitis | Increased mast cells, eosinophils in conjunctival epithelium and substantia propria Epithelial cell/goblet cell hypertrophy Increased CD4/CD8 ratio in conjunctival epithelium and substantia propria Increased collagen | Increased specific IgE antibody in tears Depressed cell-mediated immunity Increased IgE antibody and eosinophils in blood Eosinophils found in conjunctival scrapings |
Vernal keratoconjunctivitis | Increased mast cells, eosinophils in conjunctival epithelium and substantia propria Eosinophil major basic protein deposition in conjunctiva CD4+ clones from conjunctiva found to have helper function for local production of IgE antibody Increased collagen Increased ICAM-1 on corneal epithelium | Increased specific IgE/IgG antibody in tears Elevated histamine and tryptase in tears Reduced serum histaminase activity Increased serum levels of nerve growth factor and substance P |
Giant papillary conjunctivitis | Giant papillae Conjunctival thickening Mast cells in epithelium | No increased histamine in tears Increased tryptase in tears |
ICAM-1, Intercellular adhesion molecule 1; IgE, immunoglobulin E; IgG, immunoglobulin G; TNF-α, tumor necrosis factor-α.
From Adkinson NF et al: Middletons allergy principles and practice, ed 8, Philadelphia, 2014, Saunders.
TABLE E4 Topical Ophthalmic Medications for Allergic Conjunctivitis
Drug and Trade Names | Mechanism of Action and Dosing | Cautions and Adverse Events |
---|---|---|
Azelastine hydrochloride 0.05% Optivar | Antihistamine Children ≥3 yr: 1 gtt bid | Not for treatment of contact lens-related irritation; the preservative may be absorbed by soft contact lenses. Wait at least 10 min after administration before inserting soft contact lenses. |
Cetirizine 0.24% (Zerviate) ophthalmic solution | ||
Emedastine difumarate 0.05% Emadine | Antihistamine Children ≥3 yr: 1 gtt qid | Soft contact lenses should not be worn if the eye is red. Wait at least 10 min after administration before inserting soft contact lenses. |
Levocabastine hydrochloride 0.05% Livostin | Antihistamine Children ≥12 yr: 1 gtt bid-qid up to 2 wk | Not for use in patients wearing soft contact lenses during treatment. |
Pheniramine maleate | Antihistamine/vasoconstrictor | Avoid prolonged use (>3-4 days) to avoid rebound symptoms. Not for use with contact lenses. |
0.3% Naphazoline hydrochloride | Children >6 yr: 1-2 gtt qid | |
0.025% | ||
Naphcon-A, Opcon-A | ||
Cromolyn sodium 4% Crolom, Opticrom | Mast cell stabilizer Children >4 yr: 1-2 gtt q4-6h | Can be used to treat giant papillary conjunctivitis and vernal keratitis. Not for use with contact lenses. |
Lodoxamide tromethamine 0.1% Alomide | Mast cell stabilizer Children ≥2 yr: 1-2 gtt qid up to 3 mo | Can be used to treat vernal keratoconjunctivitis. Not for use in patients wearing soft contact lenses during treatment. |
Nedocromil sodium 2% Alocril | Mast cell stabilizer Children ≥3 yr: 1-2 gtt bid | Avoid wearing contact lenses while exhibiting the signs and symptoms of allergic conjunctivitis. |
Pemirolast potassium 0.1% Alamast | Mast cell stabilizer Children >3 yr: 1-2 gtt qid | Not for treatment of contact lens-related irritation; the preservative may be absorbed by soft contact lenses. Wait at least 10 min after administration before inserting soft contact lenses. |
Epinastine hydrochloride 0.05% Elestat | Antihistamine/mast cell stabilizer Children ≥3 yr: 1 gtt bid | Contact lenses should be removed before use. Wait at least 15 min after administration before inserting soft contact lenses. Not for the treatment of contact lens irritation. |
Ketotifen fumarate 0.025% Zaditor | Antihistamine/mast cell stabilizer Children ≥3 yr: 1 gtt bid q8-12h | Not for treatment of contact lens-related irritation; the preservative may be absorbed by soft contact lenses. Wait at least 10 min after administration before inserting soft contact lenses. |
Olopatadine hydrochloride 0.1%, 0.2%, 0.7% Patanol Pataday Pazeo | Antihistamine/mast cell stabilizer Children ≥3 yr: 1 gtt bid (8 hr apart) Children ≥2 yr: 1 gtt qd | Not for treatment of contact lens-related irritation; the preservative may be absorbed by soft contact lenses. Wait at least 10 min after administration before inserting soft contact lenses. |
Alcaftadine 0.25% Lastacaft | Antihistamine/mast cell stabilizer Children >2 yr: 1 gtt bid q8-12h | Contact lenses should be removed before application; may be inserted after 10 min. Not for the treatment of contact lens irritation. |
Bepotastine besilate 1.5% Bepreve | Antihistamine/mast cell stabilizer Children >2 yr: 1 gtt bid q8-12h | Contact lenses should be removed before application, may be inserted after 10 min. Not for the treatment of contact lens irritation. |
Ketorolac tromethamine 0.5% Acular | NSAID Children ≥3 yr: 1 gtt qid | Avoid with aspirin or NSAID sensitivity. Use ocular product with caution in patients with complicated ocular surgeries, corneal denervation or epithelial defects, ocular surface diseases (e.g., dry eye syndrome), repeated ocular surgeries within a short period, diabetes mellitus, or rheumatoid arthritis; these patients may be at risk for corneal adverse events that may be sight-threatening. Do not use while wearing contact lenses. |
Fluorometholone 0.1%, 0.25% suspension (0.1%, 0.25%) and ointment (0.1%) FML, FML Forte, Flarex | Fluorinated corticosteroid Children ≥2 yr, 1 gtt into conjunctival sac of affected eye(s) bid-qid. During initial 24-48 h, dosage may be increased to 1 gtt q4h. Ointment (∼1.3 cm in length) into conjunctival sac of affected eye(s) 1-3 times daily. May be applied q4h during initial 24-48 h of therapy | If improvement does not occur after 2 days, patient should be reevaluated. Patient should remove soft contact lenses before administering (contains benzalkonium chloride) and delay reinsertion of lenses for ≥15 min after administration. Close monitoring for development of glaucoma and cataracts. |
bid, Two times daily; gtt, drops; NSAID, nonsteroidal antiinflammatory drug; q4-6h, every 4-6 h; qd, every day; qid, four times daily.
From Kliegman RM: Nelson textbook of pediatrics, ed 21, Philadelphia, 2020, Elsevier.
TABLE E5 Clinical Manifestations and Treatment of Neonatal Conjunctivitis
ETIOLOGIC AGENT | CASES (%) | DISCHARGE AND EXTERNAL EXAMINATION | TYPICAL AGE AT ONSET | DIAGNOSIS | ASSOCIATED MANIFESTATIONS | TREATMENT |
---|---|---|---|---|---|---|
Chemical: silver nitrate | Variable (1%), depending on use of silver nitrate | Watery discharge | 1-3 days | No organisms on smear or culture | None | None |
Chlamydia trachomatis (inclusion conjunctivitis) | 2-40 | Scant discharge; mild swelling; hyperemia; follicular response; late corneal staining | 4-19 days | Test of discharge with a DIF test or PCR assay | May presage C. trachomatis pneumonia (at 3 wk to 3 mo of age) | Erythromycin (oral) |
Bacterial: Staphylococcus, Streptococcus, Pseudomonas, E. coli | 30-50 | Purulent moderate discharge; mild lid and conjunctival swelling; corneal involvement with risk for perforation | 2-7 days | Gram stain; culture on blood agar | Topical therapy | |
Neisseria gonorrhoeae | <1 | Copious, purulent discharge; swelling of lids and conjunctivae; corneal involvement common; risk for perforation and corneal scar | 1-7 days | Gram stain (gram-negative intracellular diplococci); culture on chocolate agar. Culture other sites including blood and CSF | May be associated with severe disseminated gonococcal infection | Ceftriaxone Hospitalize patient |
HSV | <1 | Clear or serosanguineous discharge; lid swelling; keratitis with cloudy cornea; dendrite formation | 3 days to 3 wk | Viral culture; DIF test, PCR assay | May be associated with disseminated perinatal HSV infection | Acyclovir (intravenous) |
CSF, Cerebrospinal fluid; DIF, direct immunofluorescence; HSV, herpes simplex virus; PCR, polymerase chain reaction.
From Marcdante KJ et al: Nelson essentials of pediatrics, ed 9, Philadelphia 2023, Elsevier.